“It’s like having a V8 put in an old V-dub,” Alan Crawford told The Canberra Times, describing the heart transplant that saved his life eight years ago.
The retired bronze foundry owner, now 76, walks 10,000 steps a day and mows his own lawn after receiving a donor heart transported via “heart in a box” technology at St Vincent’s Hospital Sydney in 2018. His case highlights a widening gap: Australian surgeons performed just 125 heart transplants in 2025 against an estimated 420,000 people living with heart failure, Heart Research Institute scientist Nicholas Lam told The Canberra Times.
Crawford’s journey to transplant began with an irregular heartbeat in his mid-40s and a stroke at 50, progressing to dilated cardiomyopathy that left his heart pumping at 10 per cent capacity.
An implanted cardioverter-defibrillator (ICD) delivered 26 shocks over the years — “you’re walking in public and there’s a sniper or something there and all of a sudden you just get whacked,” he told The Canberra Times — forcing his retirement from the foundry that cast the bronze soldiers for Sydney’s Anzac Bridge.

By 2018, doctors at Royal Prince Alfred Hospital had exhausted medical options. Transferred to St Vincent’s, Crawford suffered another cardiac episode almost on arrival. Days later, before formal listing, a donor heart arrived. It had been assessed via angiogram while beating inside the Organ Care System (OCS) — a first for the program — clearing an organ that might have been declined due to the donor’s family history of heart disease.
“You’re the most eager guy I’ve ever seen jumping on the operating table to have your heart cut out,” the anaesthetist told him three days post-op, Crawford recounted to The Canberra Times. He was discharged in 13 days; eight years on, his graft runs at 65 per cent ejection fraction without a pacemaker or ICD.
Ex-vivo perfusion keeps donor hearts beating during transport
- Ex-vivo perfusion keeps donor hearts beating. The “heart in a box” (OCS) circulates warm, oxygenated blood through the organ during transport, allowing surgeons to test function — like an angiogram — before transplant.
- Transplant remains rare. Only 125 procedures occurred nationally in 2025; most of the 420,000 Australians with heart failure are managed with medication and devices, not replacement organs.
- Regeneration research aims to reduce demand. Scientists are using modified RNA to reactivate fetal gene programs that drive cardiomyocyte division — potentially healing muscle after infarction without a donor organ.
The perfusion breakthrough that expanded the donor pool
Standard cold static storage preserves a heart on ice for roughly four hours. The OCS, manufactured by TransMedics, extends that window by maintaining near-physiologic perfusion — warm, oxygenated, nutrient-enriched blood — during transit. St Vincent’s Sydney adopted the system for its first 26 recipients, including Crawford.
Crucially, the platform permits functional assessment: coronary angiography on the device confirmed the donor heart was free of significant coronary artery disease despite a concerning family history, converting a “marginal” organ into a viable graft.
Regeneration: the long horizon
Dr Lam, who returned from the United States to establish the Cardiac Biology and Regeneration Lab at the Heart Research Institute, targets the fundamental limitation: adult human cardiomyocytes rarely divide. Zebrafish and neonatal mice regenerate myocardium strongly; the genetic machinery exists but is silenced after birth. “The optimistic thought is that we can do it but we’ve forgotten how to,” Dr Lam told The Canberra Times.
His team uses modified messenger RNA (modRNA) — the same platform underlying certain COVID-19 vaccines — to transiently express cell-cycle regulators (e.g., cyclin D2, CDK4, YAP) in adult cardiomyocytes, prompting controlled proliferation without genomic integration. Parallel work explores direct reprogramming: converting cardiac fibroblasts into induced cardiomyocytes via transcription factor cocktails (GMT: Gata4, Mef2c, Tbx5). Both strategies remain preclinical; Dr Lam estimates a first-in-human candidate in 10–15 years.
By the numbers: Australia’s transplant landscape
| Metric | Figure (2025) | Context |
|---|---|---|
| Heart transplants performed | 125 | National total, The Canberra Times |
| Australians with heart failure | ~420,000 | Estimated prevalence, The Canberra Times |
| OCS recipients at St Vincent’s (cumulative) | 26 | Including Crawford as #26, The Canberra Times |
| Crawford’s native EF pre-transplant | 10% | Severe systolic dysfunction, The Canberra Times |
| Crawford’s graft EF at 8 years | 65% | Normal range, The Canberra Times |
Crawford reflects on survival and years with wife
Crawford, who attended Heart Research Institute lectures regularly, reflected on the ordeal: “In a way I’m glad I went through that … and survived, of course,” he told The Canberra Times. His wife Barbara died in 2025 after 54 years of marriage; his transplanted heart allowed him to care for her at home during her final two years.
For the 420,000 Australians still waiting, the calculus remains stark: 125 donor hearts a year versus a pipeline of regenerative therapies measured in decades. “He’s one of the lucky ones,” Dr Lam told The Canberra Times. “If regenerative therapies could help some patients avoid transplantation, more donor hearts could be available for those who still need them.”
References
- The Canberra Times — “A new engine for Alan, new hope for failing hearts” (AAP reporting)
- Camden Courier — syndicated AAP report, same copy
- Central Western Daily — syndicated AAP report, same copy
- Katherine Times — syndicated AAP report, same copy
- Khush KK, et al. “Ex-vivo perfusion of donor hearts for human heart transplantation (EXPAND): a randomised, open-label, non-inferiority trial.” The Lancet. 2021;397(10292):2467-2477.
- Heart Research Institute Annual Report 2024 — funding disclosures for Cardiac Biology and Regeneration Lab.